Every open market buy and sale of Zevra Therapeutics, Inc. stock by its officers, directors and 10% owners over the last two years, straight from SEC Form 4 filings. Insiders are only selling over the last 12 months: $0 bought and $2.5M sold.
Buying and selling by month
open market, last 12 monthsGet an alert when ZVRA insiders trade
We read every Form 4 the moment the SEC posts it and tell you when an ZVRA officer, director or 10% owner buys on the open market, or sells $250K or more outside a pre-arranged plan, by email or on your phone.
Insider alerts are part of AI Pro. Start with a free account, then add AI Pro when you want the alerts.
Every ZVRA insider trade
2 years · newest first| Insider | Type | Price | Held after | Filed | |||
|---|---|---|---|---|---|---|---|
| Oct 12, 2026 | Neil F. McFarlanePresident and CEO | Sale plan | 20,000 | $11.25 | $225K | 417,225 | Oct 13Form 4 |
| Aug 14, 2026 | Rahsaan ThompsonChief Legal & Compliance | Sale plan | 42,666 | $11.13 | $475K | 37,569 | Aug 17Form 4 |
| Aug 10, 2026 | Corey Michael WattonDirector | Sale | 12,300 | $11.25 | $138K | 1,800 | Aug 12Form 4 |
| Jun 22, 2026 | Rahsaan ThompsonChief Legal & Compliance | Sale plan | 34,557 | $12.68 | $438K | 80,235 | Jun 23Form 4 |
| May 11, 2026 | Rahsaan ThompsonChief Legal & Compliance | Sale plan | 1,794 | $11.30 | $20K | 48,125 | May 13Form 4 |
| Feb 9, 2026 | Neil F. McFarlanePresident and CEO | Sale plan | 14,625 | $8.56 | $125K | 387,225 | Feb 10Form 4 |
| Feb 3, 2026 | Timothy J. SangiovanniSVP, Finance & Corp Controller | Sale plan | 3,000 | $9.18 | $28K | 29,590 | Feb 4Form 4 |
| Feb 3, 2026 | Joshua SchaferCco | Sale plan | 10,500 | $9.19 | $96K | 62,278 | Feb 4Form 4 |
| Feb 2, 2026 | Neil F. McFarlanePresident and CEO | Sale plan | 91,000 | $9.38 | $854K | 364,350 | Feb 2Form 4 |
| Jan 30, 2026 | Timothy J. SangiovanniSVP, Finance & Corp Controller | Sale plan | 1,750 | $8.82 | $15K | 20,924 | Feb 2Form 4 |
| Jan 30, 2026 | Rahsaan ThompsonChief Legal & Compliance | Sale plan | 4,080 | $8.83 | $36K | 49,919 | Feb 2Form 4 |
| Jan 30, 2026 | Adrian W QuartelChief Medical Officer | Sale plan | 4,533 | $8.83 | $40K | 9,723 | Feb 2Form 4 |
| Jan 30, 2026 | Joshua SchaferCco | Sale plan | 3,375 | $8.83 | $30K | 37,444 | Feb 2Form 4 |
| Oct 10, 2025 | Neil F. McFarlanePresident and CEO | Sale plan | 19,500 | $10.82 | $211K | 222,016 | Oct 10Form 4 |
| Sep 12, 2025 | Tamara A FavoritoDirector | Buy | 3,175 | $7.79 | $25K | 3,894 | Sep 16Form 4 |
ZVRA insider trading FAQ
Are ZVRA insiders buying or selling?
Insiders are only selling over the last 12 months. 0 insiders bought $0 of ZVRA on the open market in 0 trades, and 6 sold $2.5M in 13 trades, 95% of that under pre-arranged trading plans.
When did an ZVRA insider last buy shares?
Tamara A Favorito (Director) bought 3,175 shares for $25K on Sep 12, 2025, reported on Sep 16, 2025.
When did an ZVRA insider last sell shares?
Neil F. McFarlane (President and CEO) sold 20,000 shares for $225K on Oct 12, 2026, under a pre-arranged trading plan.
What is a Form 4?
Company officers, directors and owners of more than 10% of the shares must report trades in the company's stock to the SEC on Form 4 within two business days. This page shows open market buys and sales only. Option exercises, stock awards, gifts and shares withheld for taxes are left out, since they are not decisions to buy or sell.
Why do insider sales matter less than buys?
Insiders sell for many reasons, such as taxes, diversification or a home purchase, and many sales are scheduled months ahead under a 10b5-1 trading plan. They buy on the open market mostly when they expect the shares to rise, which is why buying, and especially several insiders buying together, gets more attention.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Trades come from SEC Form 4 filings as reported by the insiders. Insiders have two business days to report, so a trade can be a few days old when it appears. See all insider cluster buys.
From SEC Form 4 filings · Not investment advice
